CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
pramlintidedrug
Likely dose
pramlintide 15 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00842075
NCT00842075N/ACompleted
CompareCT.gov

Effects of Pramlintide in Adolescents With Type 1 Diabetes

University of Colorado, Denver·interventional·Posted Feb 12, 2009·Updated Jun 23, 2015

In Brief

A clinical study evaluating pramlintide for Type 1 Diabetes. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The investigators hypothesize that subcutaneous pramlintide as an adjunct to mealtime insulin immediately prior to meals can significantly reduce post-prandial glucose concentrations compared with mealtime insulin alone in children with type 1 diabetes. This is a 36 day, randomized, two-arm, open-label study with a treatment arm (taking pramlintide before all meals) and a control arm (diabetes regimen as usual).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsAmylin Pharmaceuticals, LLC.

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 12, 2009
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.4 years ago

Interventions

pramlintidedrug

subcutaneous injection (15 mcg initial dose)prior to meals